Skip to content

Biohaven BHVN Shares (Diluted)

Shares (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
895.9M-0.5%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
87.3M+11.0%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
47.2M+33.9%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
147.4M+7.2%
uniQure logo
uniQureQURE
62.7M+18.1%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
70.5M+12.0%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.23B-48.1%
Enterprise value$2.23B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's shares (diluted)?
Biohaven (BHVN) reported shares (diluted) of 147.6M in Q1 2026.
How has Biohaven's shares (diluted) changed year-over-year?
Biohaven's shares (diluted) increased by 44.8% year-over-year, from 101.9M to 147.6M.
What is the long-term trend for Biohaven's shares (diluted)?
Over 3 years (2022 to 2025), Biohaven's shares (diluted) has grown at a 36.9% compound annual growth rate (CAGR), from 162.9M to 417.8M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.